nodes	percent_of_prediction	percent_of_DWPC	metapath
Vandetanib—RIPK2—Crohn's disease	0.6	0.917	CbGaD
Vandetanib—ALB—Crohn's disease	0.0544	0.0832	CbGaD
Vandetanib—RET—enteric nervous system—Crohn's disease	0.011	0.114	CbGeAlD
Vandetanib—Serum amylase increased—Mesalazine—Crohn's disease	0.00549	0.0599	CcSEcCtD
Vandetanib—ORM1—bile—Crohn's disease	0.0035	0.0362	CbGeAlD
Vandetanib—LTK—mouth—Crohn's disease	0.00283	0.0292	CbGeAlD
Vandetanib—Pneumonia aspiration—Mesalazine—Crohn's disease	0.00264	0.0288	CcSEcCtD
Vandetanib—Bosutinib—LRRK2—Crohn's disease	0.00251	0.788	CrCbGaD
Vandetanib—Potassium increased—Prednisone—Crohn's disease	0.00225	0.0246	CcSEcCtD
Vandetanib—Diverticulitis—Azathioprine—Crohn's disease	0.00194	0.0212	CcSEcCtD
Vandetanib—ERBB3—Methyldopa—Mesalazine—Crohn's disease	0.00177	0.799	CbGdCrCtD
Vandetanib—Polyp—Mercaptopurine—Crohn's disease	0.00175	0.019	CcSEcCtD
Vandetanib—Chromaturia—Mesalazine—Crohn's disease	0.00161	0.0176	CcSEcCtD
Vandetanib—Intestinal perforation—Azathioprine—Crohn's disease	0.0016	0.0175	CcSEcCtD
Vandetanib—Cyst—Mercaptopurine—Crohn's disease	0.00159	0.0173	CcSEcCtD
Vandetanib—ERBB3—mouth—Crohn's disease	0.00154	0.0159	CbGeAlD
Vandetanib—PTK6—skin of body—Crohn's disease	0.0015	0.0155	CbGeAlD
Vandetanib—PTK6—mammalian vulva—Crohn's disease	0.00137	0.0141	CbGeAlD
Vandetanib—Pericarditis—Mesalazine—Crohn's disease	0.00133	0.0145	CcSEcCtD
Vandetanib—BLK—lymphoid tissue—Crohn's disease	0.00128	0.0132	CbGeAlD
Vandetanib—Nephropathy—Mesalazine—Crohn's disease	0.00121	0.0132	CcSEcCtD
Vandetanib—Amylase increased—Mesalazine—Crohn's disease	0.00121	0.0132	CcSEcCtD
Vandetanib—PTK6—digestive system—Crohn's disease	0.0012	0.0124	CbGeAlD
Vandetanib—BMPR1B—epithelium—Crohn's disease	0.0012	0.0124	CbGeAlD
Vandetanib—TYRO3—skin of body—Crohn's disease	0.00116	0.012	CbGeAlD
Vandetanib—Faecal incontinence—Mesalazine—Crohn's disease	0.00114	0.0125	CcSEcCtD
Vandetanib—Polyp—Azathioprine—Crohn's disease	0.00104	0.0113	CcSEcCtD
Vandetanib—PDGFRB—gall bladder—Crohn's disease	0.00104	0.0107	CbGeAlD
Vandetanib—Micturition urgency—Mesalazine—Crohn's disease	0.00102	0.0111	CcSEcCtD
Vandetanib—Blood potassium increased—Prednisone—Crohn's disease	0.00101	0.011	CcSEcCtD
Vandetanib—Cholecystitis—Mesalazine—Crohn's disease	0.001	0.0109	CcSEcCtD
Vandetanib—PLK4—lymphoid tissue—Crohn's disease	0.001	0.0103	CbGeAlD
Vandetanib—ORM1—gall bladder—Crohn's disease	0.000972	0.01	CbGeAlD
Vandetanib—Platelet count decreased—Mesalazine—Crohn's disease	0.000969	0.0106	CcSEcCtD
Vandetanib—STK35—skin of body—Crohn's disease	0.000967	0.00999	CbGeAlD
Vandetanib—Neoplasm—Mercaptopurine—Crohn's disease	0.00096	0.0105	CcSEcCtD
Vandetanib—Cyst—Azathioprine—Crohn's disease	0.000946	0.0103	CcSEcCtD
Vandetanib—FLT4—epithelium—Crohn's disease	0.000942	0.00974	CbGeAlD
Vandetanib—TYRO3—lymphoid tissue—Crohn's disease	0.00094	0.00971	CbGeAlD
Vandetanib—RIPK2—epithelium—Crohn's disease	0.000937	0.00968	CbGeAlD
Vandetanib—LYN—lymphoid tissue—Crohn's disease	0.000935	0.00966	CbGeAlD
Vandetanib—EPHA5—digestive system—Crohn's disease	0.000928	0.00959	CbGeAlD
Vandetanib—Cholelithiasis—Mesalazine—Crohn's disease	0.000927	0.0101	CcSEcCtD
Vandetanib—Sepsis—Mercaptopurine—Crohn's disease	0.000921	0.01	CcSEcCtD
Vandetanib—Hypomagnesaemia—Mesalazine—Crohn's disease	0.000907	0.00989	CcSEcCtD
Vandetanib—VEGFA—smooth muscle tissue—Crohn's disease	0.0009	0.00931	CbGeAlD
Vandetanib—ERBB3—epithelium—Crohn's disease	0.000897	0.00927	CbGeAlD
Vandetanib—Interstitial lung disease—Azathioprine—Crohn's disease	0.000894	0.00975	CcSEcCtD
Vandetanib—Dermatitis acneiform—Prednisone—Crohn's disease	0.000892	0.00973	CcSEcCtD
Vandetanib—RIPK2—skin of body—Crohn's disease	0.000891	0.00921	CbGeAlD
Vandetanib—Nail disorder—Mesalazine—Crohn's disease	0.000888	0.00969	CcSEcCtD
Vandetanib—ERBB3—skin of body—Crohn's disease	0.000853	0.00882	CbGeAlD
Vandetanib—ALB—gall bladder—Crohn's disease	0.000852	0.00881	CbGeAlD
Vandetanib—EGFR—mammalian vulva—Crohn's disease	0.000838	0.00866	CbGeAlD
Vandetanib—RET—epithelium—Crohn's disease	0.000832	0.0086	CbGeAlD
Vandetanib—Interstitial lung disease—Mesalazine—Crohn's disease	0.000814	0.00888	CcSEcCtD
Vandetanib—VEGFA—mammalian vulva—Crohn's disease	0.000811	0.00838	CbGeAlD
Vandetanib—FMO1—mammalian vulva—Crohn's disease	0.000806	0.00833	CbGeAlD
Vandetanib—Blood potassium decreased—Prednisone—Crohn's disease	0.000802	0.00875	CcSEcCtD
Vandetanib—FLT3—lymphoid tissue—Crohn's disease	0.000799	0.00826	CbGeAlD
Vandetanib—AXL—smooth muscle tissue—Crohn's disease	0.000798	0.00825	CbGeAlD
Vandetanib—IRAK4—mammalian vulva—Crohn's disease	0.000794	0.0082	CbGeAlD
Vandetanib—AXL—skin of body—Crohn's disease	0.000788	0.00814	CbGeAlD
Vandetanib—TEK—epithelium—Crohn's disease	0.000758	0.00783	CbGeAlD
Vandetanib—Tubulointerstitial nephritis—Mesalazine—Crohn's disease	0.000752	0.00821	CcSEcCtD
Vandetanib—FYN—smooth muscle tissue—Crohn's disease	0.000747	0.00772	CbGeAlD
Vandetanib—FYN—skin of body—Crohn's disease	0.000737	0.00762	CbGeAlD
Vandetanib—MKNK1—mammalian vulva—Crohn's disease	0.00073	0.00755	CbGeAlD
Vandetanib—TEK—smooth muscle tissue—Crohn's disease	0.00073	0.00754	CbGeAlD
Vandetanib—MAP4K5—smooth muscle tissue—Crohn's disease	0.00073	0.00754	CbGeAlD
Vandetanib—FLT4—lymphoid tissue—Crohn's disease	0.000726	0.0075	CbGeAlD
Vandetanib—BLK—lymph node—Crohn's disease	0.000723	0.00747	CbGeAlD
Vandetanib—LCK—mammalian vulva—Crohn's disease	0.000721	0.00746	CbGeAlD
Vandetanib—FGR—mammalian vulva—Crohn's disease	0.000721	0.00746	CbGeAlD
Vandetanib—AXL—mammalian vulva—Crohn's disease	0.000719	0.00743	CbGeAlD
Vandetanib—LTK—lymph node—Crohn's disease	0.000715	0.00739	CbGeAlD
Vandetanib—RIPK2—digestive system—Crohn's disease	0.000713	0.00737	CbGeAlD
Vandetanib—FMO1—digestive system—Crohn's disease	0.000707	0.00731	CbGeAlD
Vandetanib—Impaired healing—Prednisone—Crohn's disease	0.000705	0.00769	CcSEcCtD
Vandetanib—IRAK4—lymphoid tissue—Crohn's disease	0.000705	0.00728	CbGeAlD
Vandetanib—FMO3—mammalian vulva—Crohn's disease	0.000697	0.0072	CbGeAlD
Vandetanib—SLK—mammalian vulva—Crohn's disease	0.000692	0.00715	CbGeAlD
Vandetanib—ERBB3—lymphoid tissue—Crohn's disease	0.000691	0.00714	CbGeAlD
Vandetanib—EPHB6—skin of body—Crohn's disease	0.000689	0.00712	CbGeAlD
Vandetanib—Acne—Mesalazine—Crohn's disease	0.000685	0.00747	CcSEcCtD
Vandetanib—ERBB3—digestive system—Crohn's disease	0.000682	0.00705	CbGeAlD
Vandetanib—YES1—smooth muscle tissue—Crohn's disease	0.000674	0.00697	CbGeAlD
Vandetanib—SRC—epithelium—Crohn's disease	0.000673	0.00696	CbGeAlD
Vandetanib—FYN—mammalian vulva—Crohn's disease	0.000673	0.00695	CbGeAlD
Vandetanib—MAP4K5—mammalian vulva—Crohn's disease	0.000657	0.00679	CbGeAlD
Vandetanib—Proteinuria—Mesalazine—Crohn's disease	0.000656	0.00715	CcSEcCtD
Vandetanib—Pancreatitis—Mercaptopurine—Crohn's disease	0.000653	0.00712	CcSEcCtD
Vandetanib—SRC—smooth muscle tissue—Crohn's disease	0.000649	0.0067	CbGeAlD
Vandetanib—MKNK1—lymphoid tissue—Crohn's disease	0.000649	0.0067	CbGeAlD
Vandetanib—Protein urine present—Mesalazine—Crohn's disease	0.000647	0.00705	CcSEcCtD
Vandetanib—MKNK1—digestive system—Crohn's disease	0.000641	0.00662	CbGeAlD
Vandetanib—FGR—lymphoid tissue—Crohn's disease	0.000641	0.00662	CbGeAlD
Vandetanib—RET—lymphoid tissue—Crohn's disease	0.000641	0.00662	CbGeAlD
Vandetanib—SRC—skin of body—Crohn's disease	0.00064	0.00662	CbGeAlD
Vandetanib—AXL—lymphoid tissue—Crohn's disease	0.000638	0.00659	CbGeAlD
Vandetanib—FGR—digestive system—Crohn's disease	0.000633	0.00654	CbGeAlD
Vandetanib—RET—digestive system—Crohn's disease	0.000633	0.00654	CbGeAlD
Vandetanib—Hypocalcaemia—Mesalazine—Crohn's disease	0.000629	0.00686	CcSEcCtD
Vandetanib—EPHB6—mammalian vulva—Crohn's disease	0.000628	0.00649	CbGeAlD
Vandetanib—KDR—epithelium—Crohn's disease	0.000619	0.0064	CbGeAlD
Vandetanib—Blood bilirubin increased—Mesalazine—Crohn's disease	0.000609	0.00664	CcSEcCtD
Vandetanib—Colitis—Azathioprine—Crohn's disease	0.000607	0.00662	CcSEcCtD
Vandetanib—YES1—mammalian vulva—Crohn's disease	0.000607	0.00627	CbGeAlD
Vandetanib—STK10—mammalian vulva—Crohn's disease	0.000601	0.00622	CbGeAlD
Vandetanib—FYN—lymphoid tissue—Crohn's disease	0.000597	0.00617	CbGeAlD
Vandetanib—KDR—smooth muscle tissue—Crohn's disease	0.000597	0.00617	CbGeAlD
Vandetanib—FYN—digestive system—Crohn's disease	0.00059	0.0061	CbGeAlD
Vandetanib—MAP4K5—lymphoid tissue—Crohn's disease	0.000584	0.00603	CbGeAlD
Vandetanib—TEK—lymphoid tissue—Crohn's disease	0.000584	0.00603	CbGeAlD
Vandetanib—Stomatitis—Mercaptopurine—Crohn's disease	0.000579	0.00631	CcSEcCtD
Vandetanib—Neoplasm—Azathioprine—Crohn's disease	0.000572	0.00624	CcSEcCtD
Vandetanib—PLK4—lymph node—Crohn's disease	0.000564	0.00583	CbGeAlD
Vandetanib—Cystitis noninfective—Mesalazine—Crohn's disease	0.000563	0.00614	CcSEcCtD
Vandetanib—Hepatobiliary disease—Mercaptopurine—Crohn's disease	0.000562	0.00613	CcSEcCtD
Vandetanib—Cystitis—Mesalazine—Crohn's disease	0.000556	0.00607	CcSEcCtD
Vandetanib—Colitis—Mesalazine—Crohn's disease	0.000553	0.00603	CcSEcCtD
Vandetanib—YES1—lymphoid tissue—Crohn's disease	0.000539	0.00557	CbGeAlD
Vandetanib—KDR—mammalian vulva—Crohn's disease	0.000537	0.00555	CbGeAlD
Vandetanib—MAP2K5—mammalian vulva—Crohn's disease	0.000537	0.00555	CbGeAlD
Vandetanib—PDGFRB—epithelium—Crohn's disease	0.000536	0.00554	CbGeAlD
Vandetanib—STK10—lymphoid tissue—Crohn's disease	0.000534	0.00552	CbGeAlD
Vandetanib—YES1—digestive system—Crohn's disease	0.000532	0.0055	CbGeAlD
Vandetanib—Dry eye—Mesalazine—Crohn's disease	0.000532	0.0058	CcSEcCtD
Vandetanib—STK10—digestive system—Crohn's disease	0.000528	0.00545	CbGeAlD
Vandetanib—Bladder pain—Mesalazine—Crohn's disease	0.000521	0.00568	CcSEcCtD
Vandetanib—BMPR1B—lymph node—Crohn's disease	0.000519	0.00537	CbGeAlD
Vandetanib—SRC—lymphoid tissue—Crohn's disease	0.000518	0.00536	CbGeAlD
Vandetanib—PDGFRB—smooth muscle tissue—Crohn's disease	0.000516	0.00534	CbGeAlD
Vandetanib—SRC—digestive system—Crohn's disease	0.000512	0.00529	CbGeAlD
Vandetanib—PDGFRB—skin of body—Crohn's disease	0.00051	0.00527	CbGeAlD
Vandetanib—KDR—lymphoid tissue—Crohn's disease	0.000477	0.00493	CbGeAlD
Vandetanib—Hypothyroidism—Prednisone—Crohn's disease	0.000475	0.00518	CcSEcCtD
Vandetanib—Gastroenteritis—Mesalazine—Crohn's disease	0.000472	0.00515	CcSEcCtD
Vandetanib—Alopecia—Mercaptopurine—Crohn's disease	0.000471	0.00514	CcSEcCtD
Vandetanib—KDR—digestive system—Crohn's disease	0.000471	0.00487	CbGeAlD
Vandetanib—PDGFRB—mammalian vulva—Crohn's disease	0.000465	0.0048	CbGeAlD
Vandetanib—Malnutrition—Mercaptopurine—Crohn's disease	0.000464	0.00506	CcSEcCtD
Vandetanib—ABL1—smooth muscle tissue—Crohn's disease	0.00046	0.00476	CbGeAlD
Vandetanib—ABL1—skin of body—Crohn's disease	0.000454	0.0047	CbGeAlD
Vandetanib—FLT3—lymph node—Crohn's disease	0.000451	0.00466	CbGeAlD
Vandetanib—STK35—lymph node—Crohn's disease	0.000442	0.00456	CbGeAlD
Vandetanib—Atrial fibrillation—Mesalazine—Crohn's disease	0.000441	0.00481	CcSEcCtD
Vandetanib—Dermatitis bullous—Mesalazine—Crohn's disease	0.000438	0.00477	CcSEcCtD
Vandetanib—ABL2—lymph node—Crohn's disease	0.00043	0.00445	CbGeAlD
Vandetanib—Lethargy—Mesalazine—Crohn's disease	0.000427	0.00465	CcSEcCtD
Vandetanib—EGFR—lymph node—Crohn's disease	0.00042	0.00434	CbGeAlD
Vandetanib—Gastrointestinal haemorrhage—Mesalazine—Crohn's disease	0.000418	0.00456	CcSEcCtD
Vandetanib—Erlotinib—ALB—Crohn's disease	0.000414	0.13	CrCbGaD
Vandetanib—ABL1—mammalian vulva—Crohn's disease	0.000414	0.00428	CbGeAlD
Vandetanib—PDGFRB—lymphoid tissue—Crohn's disease	0.000413	0.00427	CbGeAlD
Vandetanib—FLT4—lymph node—Crohn's disease	0.000409	0.00423	CbGeAlD
Vandetanib—PDGFRB—digestive system—Crohn's disease	0.000408	0.00421	CbGeAlD
Vandetanib—RIPK2—lymph node—Crohn's disease	0.000407	0.00421	CbGeAlD
Vandetanib—VEGFA—lymph node—Crohn's disease	0.000406	0.0042	CbGeAlD
Vandetanib—Glaucoma—Prednisone—Crohn's disease	0.000405	0.00442	CcSEcCtD
Vandetanib—FMO1—lymph node—Crohn's disease	0.000404	0.00417	CbGeAlD
Vandetanib—IRAK4—lymph node—Crohn's disease	0.000398	0.00411	CbGeAlD
Vandetanib—Arthralgia—Mercaptopurine—Crohn's disease	0.000395	0.00431	CcSEcCtD
Vandetanib—Fungal infection—Prednisone—Crohn's disease	0.000395	0.00431	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Mercaptopurine—Crohn's disease	0.000392	0.00428	CcSEcCtD
Vandetanib—Blood creatinine increased—Mesalazine—Crohn's disease	0.000392	0.00427	CcSEcCtD
Vandetanib—ERBB3—lymph node—Crohn's disease	0.00039	0.00403	CbGeAlD
Vandetanib—Pancreatitis—Azathioprine—Crohn's disease	0.000389	0.00424	CcSEcCtD
Vandetanib—Dry skin—Mesalazine—Crohn's disease	0.000383	0.00418	CcSEcCtD
Vandetanib—Oedema—Mercaptopurine—Crohn's disease	0.000379	0.00413	CcSEcCtD
Vandetanib—Nasopharyngitis—Mesalazine—Crohn's disease	0.000374	0.00408	CcSEcCtD
Vandetanib—Thrombocytopenia—Mercaptopurine—Crohn's disease	0.000371	0.00404	CcSEcCtD
Vandetanib—Gastritis—Mesalazine—Crohn's disease	0.00037	0.00404	CcSEcCtD
Vandetanib—Alanine aminotransferase increased—Mesalazine—Crohn's disease	0.000369	0.00402	CcSEcCtD
Vandetanib—ABL1—lymphoid tissue—Crohn's disease	0.000368	0.0038	CbGeAlD
Vandetanib—Skin disorder—Mercaptopurine—Crohn's disease	0.000368	0.00401	CcSEcCtD
Vandetanib—Endocrine disorder—Prednisone—Crohn's disease	0.000368	0.00401	CcSEcCtD
Vandetanib—MKNK1—lymph node—Crohn's disease	0.000366	0.00378	CbGeAlD
Vandetanib—ABL1—digestive system—Crohn's disease	0.000363	0.00376	CbGeAlD
Vandetanib—Acne—Prednisone—Crohn's disease	0.000362	0.00395	CcSEcCtD
Vandetanib—Dysphagia—Mesalazine—Crohn's disease	0.000361	0.00394	CcSEcCtD
Vandetanib—Influenza—Mesalazine—Crohn's disease	0.000361	0.00394	CcSEcCtD
Vandetanib—LCK—lymph node—Crohn's disease	0.000361	0.00374	CbGeAlD
Vandetanib—RET—lymph node—Crohn's disease	0.000361	0.00374	CbGeAlD
Vandetanib—FGR—lymph node—Crohn's disease	0.000361	0.00374	CbGeAlD
Vandetanib—AXL—lymph node—Crohn's disease	0.00036	0.00372	CbGeAlD
Vandetanib—Pneumonia—Azathioprine—Crohn's disease	0.000356	0.00388	CcSEcCtD
Vandetanib—Bronchospasm—Mesalazine—Crohn's disease	0.000356	0.00388	CcSEcCtD
Vandetanib—Pancreatitis—Mesalazine—Crohn's disease	0.000354	0.00387	CcSEcCtD
Vandetanib—Infestation NOS—Azathioprine—Crohn's disease	0.000354	0.00386	CcSEcCtD
Vandetanib—Infestation—Azathioprine—Crohn's disease	0.000354	0.00386	CcSEcCtD
Vandetanib—Stevens-Johnson syndrome—Azathioprine—Crohn's disease	0.000351	0.00383	CcSEcCtD
Vandetanib—FMO3—lymph node—Crohn's disease	0.000349	0.00361	CbGeAlD
Vandetanib—Bronchitis—Mesalazine—Crohn's disease	0.000348	0.00379	CcSEcCtD
Vandetanib—SLK—lymph node—Crohn's disease	0.000347	0.00358	CbGeAlD
Vandetanib—Musculoskeletal discomfort—Mercaptopurine—Crohn's disease	0.000345	0.00376	CcSEcCtD
Vandetanib—Neutropenia—Mesalazine—Crohn's disease	0.000338	0.00369	CcSEcCtD
Vandetanib—Dysuria—Mesalazine—Crohn's disease	0.000338	0.00369	CcSEcCtD
Vandetanib—FYN—lymph node—Crohn's disease	0.000337	0.00348	CbGeAlD
Vandetanib—Upper respiratory tract infection—Mesalazine—Crohn's disease	0.000336	0.00366	CcSEcCtD
Vandetanib—Hepatobiliary disease—Azathioprine—Crohn's disease	0.000335	0.00365	CcSEcCtD
Vandetanib—Pollakiuria—Mesalazine—Crohn's disease	0.000334	0.00364	CcSEcCtD
Vandetanib—Photosensitivity reaction—Mesalazine—Crohn's disease	0.00033	0.0036	CcSEcCtD
Vandetanib—Decreased appetite—Mercaptopurine—Crohn's disease	0.000329	0.00359	CcSEcCtD
Vandetanib—MAP4K5—lymph node—Crohn's disease	0.000329	0.0034	CbGeAlD
Vandetanib—TEK—lymph node—Crohn's disease	0.000329	0.0034	CbGeAlD
Vandetanib—Weight decreased—Mesalazine—Crohn's disease	0.000327	0.00357	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Mercaptopurine—Crohn's disease	0.000327	0.00357	CcSEcCtD
Vandetanib—Pneumonia—Mesalazine—Crohn's disease	0.000324	0.00354	CcSEcCtD
Vandetanib—Infestation—Mesalazine—Crohn's disease	0.000322	0.00352	CcSEcCtD
Vandetanib—Infestation NOS—Mesalazine—Crohn's disease	0.000322	0.00352	CcSEcCtD
Vandetanib—Depression—Mesalazine—Crohn's disease	0.000321	0.0035	CcSEcCtD
Vandetanib—Cataract—Prednisone—Crohn's disease	0.00032	0.00349	CcSEcCtD
Vandetanib—Stevens-Johnson syndrome—Mesalazine—Crohn's disease	0.00032	0.00348	CcSEcCtD
Vandetanib—Haemoglobin—Azathioprine—Crohn's disease	0.000319	0.00348	CcSEcCtD
Vandetanib—Haemorrhage—Azathioprine—Crohn's disease	0.000318	0.00346	CcSEcCtD
Vandetanib—Renal failure—Mesalazine—Crohn's disease	0.000317	0.00346	CcSEcCtD
Vandetanib—ABCC1—mammalian vulva—Crohn's disease	0.000316	0.00326	CbGeAlD
Vandetanib—EPHB6—lymph node—Crohn's disease	0.000315	0.00325	CbGeAlD
Vandetanib—Stomatitis—Mesalazine—Crohn's disease	0.000314	0.00343	CcSEcCtD
Vandetanib—Conjunctivitis—Mesalazine—Crohn's disease	0.000313	0.00342	CcSEcCtD
Vandetanib—Urinary tract infection—Mesalazine—Crohn's disease	0.000313	0.00342	CcSEcCtD
Vandetanib—Haematuria—Mesalazine—Crohn's disease	0.000307	0.00335	CcSEcCtD
Vandetanib—Hepatobiliary disease—Mesalazine—Crohn's disease	0.000305	0.00332	CcSEcCtD
Vandetanib—YES1—lymph node—Crohn's disease	0.000304	0.00314	CbGeAlD
Vandetanib—Epistaxis—Mesalazine—Crohn's disease	0.000304	0.00332	CcSEcCtD
Vandetanib—Sinusitis—Mesalazine—Crohn's disease	0.000302	0.0033	CcSEcCtD
Vandetanib—STK10—lymph node—Crohn's disease	0.000301	0.00311	CbGeAlD
Vandetanib—Erythema multiforme—Azathioprine—Crohn's disease	0.0003	0.00328	CcSEcCtD
Vandetanib—Body temperature increased—Mercaptopurine—Crohn's disease	0.000299	0.00327	CcSEcCtD
Vandetanib—SRC—lymph node—Crohn's disease	0.000293	0.00302	CbGeAlD
Vandetanib—Haemoglobin—Mesalazine—Crohn's disease	0.000291	0.00317	CcSEcCtD
Vandetanib—Haemorrhage—Mesalazine—Crohn's disease	0.000289	0.00316	CcSEcCtD
Vandetanib—Mediastinal disorder—Azathioprine—Crohn's disease	0.000286	0.00312	CcSEcCtD
Vandetanib—Urinary tract disorder—Mesalazine—Crohn's disease	0.000286	0.00312	CcSEcCtD
Vandetanib—Arrhythmia—Azathioprine—Crohn's disease	0.000284	0.00309	CcSEcCtD
Vandetanib—Urethral disorder—Mesalazine—Crohn's disease	0.000284	0.00309	CcSEcCtD
Vandetanib—Alopecia—Azathioprine—Crohn's disease	0.000281	0.00306	CcSEcCtD
Vandetanib—Erythema multiforme—Mesalazine—Crohn's disease	0.000274	0.00298	CcSEcCtD
Vandetanib—Eye disorder—Mesalazine—Crohn's disease	0.00027	0.00295	CcSEcCtD
Vandetanib—KDR—lymph node—Crohn's disease	0.000269	0.00278	CbGeAlD
Vandetanib—MAP2K5—lymph node—Crohn's disease	0.000269	0.00278	CbGeAlD
Vandetanib—Cardiac disorder—Mesalazine—Crohn's disease	0.000269	0.00293	CcSEcCtD
Vandetanib—Sepsis—Prednisone—Crohn's disease	0.000265	0.00289	CcSEcCtD
Vandetanib—Angiopathy—Mesalazine—Crohn's disease	0.000263	0.00286	CcSEcCtD
Vandetanib—ABCG2—mammalian vulva—Crohn's disease	0.000261	0.0027	CbGeAlD
Vandetanib—Mediastinal disorder—Mesalazine—Crohn's disease	0.000261	0.00284	CcSEcCtD
Vandetanib—Gefitinib—ALB—Crohn's disease	0.000259	0.0815	CrCbGaD
Vandetanib—Diarrhoea—Mercaptopurine—Crohn's disease	0.000259	0.00283	CcSEcCtD
Vandetanib—Alopecia—Mesalazine—Crohn's disease	0.000256	0.00279	CcSEcCtD
Vandetanib—Mental disorder—Mesalazine—Crohn's disease	0.000253	0.00276	CcSEcCtD
Vandetanib—Dysgeusia—Mesalazine—Crohn's disease	0.000247	0.00269	CcSEcCtD
Vandetanib—Muscle spasms—Mesalazine—Crohn's disease	0.000242	0.00264	CcSEcCtD
Vandetanib—Vomiting—Mercaptopurine—Crohn's disease	0.000241	0.00263	CcSEcCtD
Vandetanib—Rash—Mercaptopurine—Crohn's disease	0.000239	0.0026	CcSEcCtD
Vandetanib—Dermatitis—Mercaptopurine—Crohn's disease	0.000239	0.0026	CcSEcCtD
Vandetanib—Vision blurred—Mesalazine—Crohn's disease	0.000237	0.00259	CcSEcCtD
Vandetanib—Tremor—Mesalazine—Crohn's disease	0.000236	0.00257	CcSEcCtD
Vandetanib—Arthralgia—Azathioprine—Crohn's disease	0.000235	0.00257	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—Crohn's disease	0.000234	0.00255	CcSEcCtD
Vandetanib—PDGFRB—lymph node—Crohn's disease	0.000233	0.00241	CbGeAlD
Vandetanib—Cardiac failure—Prednisone—Crohn's disease	0.000227	0.00247	CcSEcCtD
Vandetanib—Lethargy—Prednisone—Crohn's disease	0.000226	0.00246	CcSEcCtD
Vandetanib—Nausea—Mercaptopurine—Crohn's disease	0.000225	0.00245	CcSEcCtD
Vandetanib—Infection—Azathioprine—Crohn's disease	0.000224	0.00245	CcSEcCtD
Vandetanib—VEGFA—Dexamethasone—Prednisone—Crohn's disease	0.000223	0.101	CbGdCrCtD
Vandetanib—VEGFA—Betamethasone—Prednisone—Crohn's disease	0.000223	0.101	CbGdCrCtD
Vandetanib—Loss of consciousness—Mesalazine—Crohn's disease	0.000221	0.00241	CcSEcCtD
Vandetanib—Gastrointestinal haemorrhage—Prednisone—Crohn's disease	0.000221	0.00241	CcSEcCtD
Vandetanib—Thrombocytopenia—Azathioprine—Crohn's disease	0.000221	0.00241	CcSEcCtD
Vandetanib—Cough—Mesalazine—Crohn's disease	0.00022	0.0024	CcSEcCtD
Vandetanib—Skin disorder—Azathioprine—Crohn's disease	0.000219	0.00239	CcSEcCtD
Vandetanib—ORM1—lymph node—Crohn's disease	0.000218	0.00226	CbGeAlD
Vandetanib—Hypertension—Mesalazine—Crohn's disease	0.000217	0.00237	CcSEcCtD
Vandetanib—Chest pain—Mesalazine—Crohn's disease	0.000214	0.00234	CcSEcCtD
Vandetanib—Arthralgia—Mesalazine—Crohn's disease	0.000214	0.00234	CcSEcCtD
Vandetanib—Anxiety—Mesalazine—Crohn's disease	0.000214	0.00233	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Mesalazine—Crohn's disease	0.000213	0.00232	CcSEcCtD
Vandetanib—Cardiac arrest—Prednisone—Crohn's disease	0.00021	0.00229	CcSEcCtD
Vandetanib—Dry mouth—Mesalazine—Crohn's disease	0.00021	0.00229	CcSEcCtD
Vandetanib—ABL1—lymph node—Crohn's disease	0.000208	0.00215	CbGeAlD
Vandetanib—Musculoskeletal discomfort—Azathioprine—Crohn's disease	0.000206	0.00224	CcSEcCtD
Vandetanib—Oedema—Mesalazine—Crohn's disease	0.000206	0.00224	CcSEcCtD
Vandetanib—Infection—Mesalazine—Crohn's disease	0.000204	0.00223	CcSEcCtD
Vandetanib—Dry skin—Prednisone—Crohn's disease	0.000203	0.00221	CcSEcCtD
Vandetanib—Nervous system disorder—Mesalazine—Crohn's disease	0.000202	0.0022	CcSEcCtD
Vandetanib—Hypokalaemia—Prednisone—Crohn's disease	0.000201	0.0022	CcSEcCtD
Vandetanib—Thrombocytopenia—Mesalazine—Crohn's disease	0.000201	0.0022	CcSEcCtD
Vandetanib—Skin disorder—Mesalazine—Crohn's disease	0.0002	0.00218	CcSEcCtD
Vandetanib—Alanine aminotransferase increased—Prednisone—Crohn's disease	0.000195	0.00213	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Azathioprine—Crohn's disease	0.000195	0.00212	CcSEcCtD
Vandetanib—ALB—lymph node—Crohn's disease	0.000192	0.00198	CbGeAlD
Vandetanib—Pancreatitis—Prednisone—Crohn's disease	0.000188	0.00205	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Mesalazine—Crohn's disease	0.000187	0.00204	CcSEcCtD
Vandetanib—Insomnia—Mesalazine—Crohn's disease	0.000186	0.00203	CcSEcCtD
Vandetanib—Paraesthesia—Mesalazine—Crohn's disease	0.000185	0.00201	CcSEcCtD
Vandetanib—Gastrointestinal pain—Azathioprine—Crohn's disease	0.000185	0.00201	CcSEcCtD
Vandetanib—Dyspnoea—Mesalazine—Crohn's disease	0.000183	0.002	CcSEcCtD
Vandetanib—Dyspepsia—Mesalazine—Crohn's disease	0.000181	0.00197	CcSEcCtD
Vandetanib—Neutropenia—Prednisone—Crohn's disease	0.000179	0.00195	CcSEcCtD
Vandetanib—Decreased appetite—Mesalazine—Crohn's disease	0.000179	0.00195	CcSEcCtD
Vandetanib—Abdominal pain—Azathioprine—Crohn's disease	0.000178	0.00195	CcSEcCtD
Vandetanib—Body temperature increased—Azathioprine—Crohn's disease	0.000178	0.00195	CcSEcCtD
Vandetanib—Gastrointestinal disorder—Mesalazine—Crohn's disease	0.000177	0.00194	CcSEcCtD
Vandetanib—Fatigue—Mesalazine—Crohn's disease	0.000177	0.00193	CcSEcCtD
Vandetanib—Constipation—Mesalazine—Crohn's disease	0.000176	0.00192	CcSEcCtD
Vandetanib—Pain—Mesalazine—Crohn's disease	0.000176	0.00192	CcSEcCtD
Vandetanib—Weight decreased—Prednisone—Crohn's disease	0.000173	0.00189	CcSEcCtD
Vandetanib—Hyperglycaemia—Prednisone—Crohn's disease	0.000173	0.00188	CcSEcCtD
Vandetanib—Depression—Prednisone—Crohn's disease	0.00017	0.00185	CcSEcCtD
Vandetanib—Gastrointestinal pain—Mesalazine—Crohn's disease	0.000168	0.00183	CcSEcCtD
Vandetanib—Body temperature increased—Mesalazine—Crohn's disease	0.000163	0.00177	CcSEcCtD
Vandetanib—Abdominal pain—Mesalazine—Crohn's disease	0.000163	0.00177	CcSEcCtD
Vandetanib—CYP3A4—digestive system—Crohn's disease	0.00016	0.00165	CbGeAlD
Vandetanib—ABCC1—lymph node—Crohn's disease	0.000158	0.00163	CbGeAlD
Vandetanib—Bradycardia—Prednisone—Crohn's disease	0.000156	0.0017	CcSEcCtD
Vandetanib—Diarrhoea—Azathioprine—Crohn's disease	0.000154	0.00168	CcSEcCtD
Vandetanib—Haemoglobin—Prednisone—Crohn's disease	0.000154	0.00168	CcSEcCtD
Vandetanib—Haemorrhage—Prednisone—Crohn's disease	0.000153	0.00167	CcSEcCtD
Vandetanib—Dizziness—Azathioprine—Crohn's disease	0.000149	0.00163	CcSEcCtD
Vandetanib—Asthenia—Mesalazine—Crohn's disease	0.000147	0.00161	CcSEcCtD
Vandetanib—Pruritus—Mesalazine—Crohn's disease	0.000145	0.00159	CcSEcCtD
Vandetanib—Vomiting—Azathioprine—Crohn's disease	0.000143	0.00156	CcSEcCtD
Vandetanib—Eye disorder—Prednisone—Crohn's disease	0.000143	0.00156	CcSEcCtD
Vandetanib—Rash—Azathioprine—Crohn's disease	0.000142	0.00155	CcSEcCtD
Vandetanib—Dermatitis—Azathioprine—Crohn's disease	0.000142	0.00155	CcSEcCtD
Vandetanib—Headache—Azathioprine—Crohn's disease	0.000141	0.00154	CcSEcCtD
Vandetanib—Diarrhoea—Mesalazine—Crohn's disease	0.000141	0.00153	CcSEcCtD
Vandetanib—Angiopathy—Prednisone—Crohn's disease	0.000139	0.00151	CcSEcCtD
Vandetanib—Arrhythmia—Prednisone—Crohn's disease	0.000137	0.00149	CcSEcCtD
Vandetanib—Dizziness—Mesalazine—Crohn's disease	0.000136	0.00148	CcSEcCtD
Vandetanib—Alopecia—Prednisone—Crohn's disease	0.000135	0.00148	CcSEcCtD
Vandetanib—Mental disorder—Prednisone—Crohn's disease	0.000134	0.00146	CcSEcCtD
Vandetanib—Nausea—Azathioprine—Crohn's disease	0.000134	0.00146	CcSEcCtD
Vandetanib—Malnutrition—Prednisone—Crohn's disease	0.000133	0.00145	CcSEcCtD
Vandetanib—ABCG2—lymph node—Crohn's disease	0.000131	0.00135	CbGeAlD
Vandetanib—Vomiting—Mesalazine—Crohn's disease	0.000131	0.00143	CcSEcCtD
Vandetanib—Rash—Mesalazine—Crohn's disease	0.00013	0.00141	CcSEcCtD
Vandetanib—Dermatitis—Mesalazine—Crohn's disease	0.000129	0.00141	CcSEcCtD
Vandetanib—Headache—Mesalazine—Crohn's disease	0.000129	0.0014	CcSEcCtD
Vandetanib—Vision blurred—Prednisone—Crohn's disease	0.000126	0.00137	CcSEcCtD
Vandetanib—Nausea—Mesalazine—Crohn's disease	0.000122	0.00133	CcSEcCtD
Vandetanib—Loss of consciousness—Prednisone—Crohn's disease	0.000117	0.00128	CcSEcCtD
Vandetanib—Convulsion—Prednisone—Crohn's disease	0.000115	0.00126	CcSEcCtD
Vandetanib—Hypertension—Prednisone—Crohn's disease	0.000115	0.00125	CcSEcCtD
Vandetanib—Arthralgia—Prednisone—Crohn's disease	0.000113	0.00124	CcSEcCtD
Vandetanib—Anxiety—Prednisone—Crohn's disease	0.000113	0.00123	CcSEcCtD
Vandetanib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—Crohn's disease	0.000113	0.00123	CcSEcCtD
Vandetanib—Oedema—Prednisone—Crohn's disease	0.000109	0.00119	CcSEcCtD
Vandetanib—Infection—Prednisone—Crohn's disease	0.000108	0.00118	CcSEcCtD
Vandetanib—Nervous system disorder—Prednisone—Crohn's disease	0.000107	0.00116	CcSEcCtD
Vandetanib—Skin disorder—Prednisone—Crohn's disease	0.000106	0.00115	CcSEcCtD
Vandetanib—Musculoskeletal discomfort—Prednisone—Crohn's disease	9.91e-05	0.00108	CcSEcCtD
Vandetanib—Insomnia—Prednisone—Crohn's disease	9.84e-05	0.00107	CcSEcCtD
Vandetanib—Paraesthesia—Prednisone—Crohn's disease	9.77e-05	0.00107	CcSEcCtD
Vandetanib—Dyspepsia—Prednisone—Crohn's disease	9.57e-05	0.00104	CcSEcCtD
Vandetanib—Decreased appetite—Prednisone—Crohn's disease	9.45e-05	0.00103	CcSEcCtD
Vandetanib—Fatigue—Prednisone—Crohn's disease	9.38e-05	0.00102	CcSEcCtD
Vandetanib—Constipation—Prednisone—Crohn's disease	9.3e-05	0.00101	CcSEcCtD
Vandetanib—Gastrointestinal pain—Prednisone—Crohn's disease	8.89e-05	0.00097	CcSEcCtD
Vandetanib—Abdominal pain—Prednisone—Crohn's disease	8.6e-05	0.000938	CcSEcCtD
Vandetanib—Body temperature increased—Prednisone—Crohn's disease	8.6e-05	0.000938	CcSEcCtD
Vandetanib—Asthenia—Prednisone—Crohn's disease	7.8e-05	0.000851	CcSEcCtD
Vandetanib—Pruritus—Prednisone—Crohn's disease	7.7e-05	0.000839	CcSEcCtD
Vandetanib—Diarrhoea—Prednisone—Crohn's disease	7.44e-05	0.000812	CcSEcCtD
Vandetanib—Dizziness—Prednisone—Crohn's disease	7.19e-05	0.000784	CcSEcCtD
Vandetanib—Vomiting—Prednisone—Crohn's disease	6.92e-05	0.000754	CcSEcCtD
Vandetanib—Rash—Prednisone—Crohn's disease	6.86e-05	0.000748	CcSEcCtD
Vandetanib—Dermatitis—Prednisone—Crohn's disease	6.85e-05	0.000747	CcSEcCtD
Vandetanib—Headache—Prednisone—Crohn's disease	6.81e-05	0.000743	CcSEcCtD
Vandetanib—Nausea—Prednisone—Crohn's disease	6.46e-05	0.000705	CcSEcCtD
Vandetanib—ABL1—Developmental Biology—TNF—Crohn's disease	6.12e-06	4.03e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—SOCS1—Crohn's disease	6.12e-06	4.03e-05	CbGpPWpGaD
Vandetanib—BLK—Immune System—STAT3—Crohn's disease	6.1e-06	4.01e-05	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—STAT3—Crohn's disease	6.09e-06	4.01e-05	CbGpPWpGaD
Vandetanib—MKNK1—Disease—IL6—Crohn's disease	6.08e-06	4e-05	CbGpPWpGaD
Vandetanib—FGR—Immune System—STAT3—Crohn's disease	6.07e-06	4e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—IL2RA—Crohn's disease	6.07e-06	4e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—SMAD3—Crohn's disease	6.06e-06	3.99e-05	CbGpPWpGaD
Vandetanib—FYN—Developmental Biology—TNF—Crohn's disease	6.06e-06	3.99e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—IL18—Crohn's disease	6.06e-06	3.99e-05	CbGpPWpGaD
Vandetanib—EGFR—Developmental Biology—STAT3—Crohn's disease	6.05e-06	3.98e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—SOCS1—Crohn's disease	5.99e-06	3.95e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—RBX1—Crohn's disease	5.99e-06	3.94e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—RIPK2—Crohn's disease	5.97e-06	3.93e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—CRP—Crohn's disease	5.95e-06	3.91e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—UBE2D1—Crohn's disease	5.93e-06	3.9e-05	CbGpPWpGaD
Vandetanib—EGFR—Axon guidance—IL6—Crohn's disease	5.92e-06	3.9e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—SOCS1—Crohn's disease	5.9e-06	3.88e-05	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—CD4—Crohn's disease	5.88e-06	3.87e-05	CbGpPWpGaD
Vandetanib—YES1—Innate Immune System—IL6—Crohn's disease	5.88e-06	3.87e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—TYK2—Crohn's disease	5.85e-06	3.85e-05	CbGpPWpGaD
Vandetanib—YES1—Immune System—IL1B—Crohn's disease	5.85e-06	3.85e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—PTGER4—Crohn's disease	5.83e-06	3.84e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—IL3—Crohn's disease	5.82e-06	3.83e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—RIPK2—Crohn's disease	5.75e-06	3.78e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PLA2G4F—Crohn's disease	5.75e-06	3.78e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—CRP—Crohn's disease	5.73e-06	3.77e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—TLR4—Crohn's disease	5.7e-06	3.75e-05	CbGpPWpGaD
Vandetanib—SRC—Adaptive Immune System—CD4—Crohn's disease	5.65e-06	3.72e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—RASGRP1—Crohn's disease	5.63e-06	3.7e-05	CbGpPWpGaD
Vandetanib—BMPR1B—Signaling Pathways—IL6—Crohn's disease	5.62e-06	3.7e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—IL3—Crohn's disease	5.61e-06	3.69e-05	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—STAT3—Crohn's disease	5.59e-06	3.68e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—JAK2—Crohn's disease	5.58e-06	3.67e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling by NGF—IL6—Crohn's disease	5.58e-06	3.67e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—TLR4—Crohn's disease	5.49e-06	3.62e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—ICAM1—Crohn's disease	5.47e-06	3.6e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—RASGRP1—Crohn's disease	5.42e-06	3.57e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—IL2RA—Crohn's disease	5.38e-06	3.54e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—SMAD3—Crohn's disease	5.36e-06	3.53e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—TYK2—Crohn's disease	5.35e-06	3.52e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—TYK2—Crohn's disease	5.33e-06	3.51e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—SMAD3—Crohn's disease	5.29e-06	3.48e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—ICAM1—Crohn's disease	5.27e-06	3.47e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—UBE2D1—Crohn's disease	5.25e-06	3.46e-05	CbGpPWpGaD
Vandetanib—EGFR—Developmental Biology—TNF—Crohn's disease	5.23e-06	3.44e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—TYK2—Crohn's disease	5.22e-06	3.44e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—TYK2—Crohn's disease	5.21e-06	3.43e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—TYK2—Crohn's disease	5.2e-06	3.42e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—SMAD3—Crohn's disease	5.17e-06	3.41e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—TYK2—Crohn's disease	5.16e-06	3.4e-05	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—STAT3—Crohn's disease	5.16e-06	3.4e-05	CbGpPWpGaD
Vandetanib—ERBB3—Disease—STAT3—Crohn's disease	5.16e-06	3.4e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—TYK2—Crohn's disease	5.14e-06	3.38e-05	CbGpPWpGaD
Vandetanib—FLT4—Signaling Pathways—IL6—Crohn's disease	5.14e-06	3.38e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—JAK2—Crohn's disease	5.1e-06	3.36e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—SOCS1—Crohn's disease	5.1e-06	3.36e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—SMAD3—Crohn's disease	5.09e-06	3.35e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—CXCL8—Crohn's disease	5.09e-06	3.35e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—RIPK2—Crohn's disease	5.09e-06	3.35e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—JAK2—Crohn's disease	5.09e-06	3.35e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—CRP—Crohn's disease	5.07e-06	3.34e-05	CbGpPWpGaD
Vandetanib—SRC—Axon guidance—IL6—Crohn's disease	5.05e-06	3.32e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—IFNG—Crohn's disease	4.99e-06	3.29e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—JAK2—Crohn's disease	4.98e-06	3.28e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—JAK2—Crohn's disease	4.97e-06	3.27e-05	CbGpPWpGaD
Vandetanib—LYN—Developmental Biology—IL6—Crohn's disease	4.96e-06	3.27e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IL3—Crohn's disease	4.96e-06	3.27e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—JAK2—Crohn's disease	4.96e-06	3.26e-05	CbGpPWpGaD
Vandetanib—ABL1—Developmental Biology—IL6—Crohn's disease	4.94e-06	3.25e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—TYK2—Crohn's disease	4.92e-06	3.24e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—JAK2—Crohn's disease	4.92e-06	3.24e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—SOCS1—Crohn's disease	4.91e-06	3.23e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—JAK2—Crohn's disease	4.9e-06	3.23e-05	CbGpPWpGaD
Vandetanib—YES1—Immune System—STAT3—Crohn's disease	4.9e-06	3.23e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—IL2RA—Crohn's disease	4.89e-06	3.22e-05	CbGpPWpGaD
Vandetanib—IRAK4—Immune System—IL6—Crohn's disease	4.89e-06	3.22e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—IFNG—Crohn's disease	4.89e-06	3.22e-05	CbGpPWpGaD
Vandetanib—FYN—Developmental Biology—IL6—Crohn's disease	4.89e-06	3.22e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—MTMR3—Crohn's disease	4.89e-06	3.22e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—IFNG—Crohn's disease	4.87e-06	3.2e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—TLR4—Crohn's disease	4.86e-06	3.2e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—TYK2—Crohn's disease	4.86e-06	3.2e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—CD4—Crohn's disease	4.82e-06	3.18e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—IFNG—Crohn's disease	4.81e-06	3.17e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—RASGRP1—Crohn's disease	4.8e-06	3.16e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—IL2RA—Crohn's disease	4.79e-06	3.15e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—TYK2—Crohn's disease	4.75e-06	3.12e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—CD4—Crohn's disease	4.72e-06	3.11e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—IL2RA—Crohn's disease	4.72e-06	3.11e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—CD4—Crohn's disease	4.7e-06	3.09e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—JAK2—Crohn's disease	4.7e-06	3.09e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—TYK2—Crohn's disease	4.69e-06	3.09e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—ICAM1—Crohn's disease	4.66e-06	3.07e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—CXCL8—Crohn's disease	4.66e-06	3.07e-05	CbGpPWpGaD
Vandetanib—ALB—Hemostasis—JAK2—Crohn's disease	4.65e-06	3.06e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—CD4—Crohn's disease	4.65e-06	3.06e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—JAK2—Crohn's disease	4.64e-06	3.05e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—CXCL8—Crohn's disease	4.54e-06	2.99e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—JAK2—Crohn's disease	4.53e-06	2.98e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—TYK2—Crohn's disease	4.53e-06	2.98e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—CXCL8—Crohn's disease	4.49e-06	2.96e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Innate Immune System—IL6—Crohn's disease	4.48e-06	2.95e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—JAK2—Crohn's disease	4.47e-06	2.94e-05	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—TNF—Crohn's disease	4.46e-06	2.94e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—IL1B—Crohn's disease	4.45e-06	2.93e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—CD4—Crohn's disease	4.45e-06	2.93e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—TYK2—Crohn's disease	4.44e-06	2.92e-05	CbGpPWpGaD
Vandetanib—RIPK2—Immune System—IL6—Crohn's disease	4.43e-06	2.91e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—PTGS2—Crohn's disease	4.42e-06	2.91e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—SMAD3—Crohn's disease	4.4e-06	2.9e-05	CbGpPWpGaD
Vandetanib—LYN—Innate Immune System—IL6—Crohn's disease	4.38e-06	2.89e-05	CbGpPWpGaD
Vandetanib—ABL1—Innate Immune System—IL6—Crohn's disease	4.36e-06	2.87e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—IL1B—Crohn's disease	4.36e-06	2.87e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—TYK2—Crohn's disease	4.35e-06	2.86e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—SOCS1—Crohn's disease	4.35e-06	2.86e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—IL1B—Crohn's disease	4.34e-06	2.86e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—JAK2—Crohn's disease	4.32e-06	2.84e-05	CbGpPWpGaD
Vandetanib—FYN—Innate Immune System—IL6—Crohn's disease	4.32e-06	2.84e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—IL1B—Crohn's disease	4.29e-06	2.83e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—CD4—Crohn's disease	4.29e-06	2.83e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—TYK2—Crohn's disease	4.28e-06	2.82e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—PTGS2—Crohn's disease	4.26e-06	2.8e-05	CbGpPWpGaD
Vandetanib—BLK—Immune System—IL6—Crohn's disease	4.26e-06	2.8e-05	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—IL6—Crohn's disease	4.26e-06	2.8e-05	CbGpPWpGaD
Vandetanib—FGR—Immune System—IL6—Crohn's disease	4.24e-06	2.79e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—SMAD3—Crohn's disease	4.24e-06	2.79e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—JAK2—Crohn's disease	4.24e-06	2.79e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—CXCL8—Crohn's disease	4.23e-06	2.79e-05	CbGpPWpGaD
Vandetanib—EGFR—Developmental Biology—IL6—Crohn's disease	4.22e-06	2.78e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—IFNG—Crohn's disease	4.16e-06	2.74e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—JAK2—Crohn's disease	4.15e-06	2.73e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—TYK2—Crohn's disease	4.1e-06	2.7e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—STAT3—Crohn's disease	4.1e-06	2.7e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—JAK2—Crohn's disease	4.08e-06	2.69e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—CXCL8—Crohn's disease	4.08e-06	2.69e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—IL2RA—Crohn's disease	4.08e-06	2.68e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—CD4—Crohn's disease	4.02e-06	2.64e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—IFNG—Crohn's disease	4.01e-06	2.64e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism of lipids and lipoproteins—PTGS2—Crohn's disease	3.99e-06	2.63e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—TYK2—Crohn's disease	3.95e-06	2.6e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—CXCL8—Crohn's disease	3.94e-06	2.6e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—CD4—Crohn's disease	3.93e-06	2.59e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—IL2RA—Crohn's disease	3.93e-06	2.59e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—JAK2—Crohn's disease	3.91e-06	2.58e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—PTGS2—Crohn's disease	3.91e-06	2.57e-05	CbGpPWpGaD
Vandetanib—ERBB3—Immune System—IL6—Crohn's disease	3.9e-06	2.57e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—CD4—Crohn's disease	3.87e-06	2.55e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—FADS1—Crohn's disease	3.81e-06	2.51e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—TYK2—Crohn's disease	3.79e-06	2.49e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—JAK2—Crohn's disease	3.77e-06	2.48e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—SMAD3—Crohn's disease	3.76e-06	2.47e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—STAT3—Crohn's disease	3.75e-06	2.47e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—ALB—Crohn's disease	3.74e-06	2.46e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—STAT3—Crohn's disease	3.73e-06	2.46e-05	CbGpPWpGaD
Vandetanib—EGFR—Innate Immune System—IL6—Crohn's disease	3.73e-06	2.46e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—IL1B—Crohn's disease	3.71e-06	2.44e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—CD4—Crohn's disease	3.71e-06	2.44e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—PTGS2—Crohn's disease	3.68e-06	2.42e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—STAT3—Crohn's disease	3.66e-06	2.41e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—STAT3—Crohn's disease	3.65e-06	2.4e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—STAT3—Crohn's disease	3.64e-06	2.4e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—JAK2—Crohn's disease	3.61e-06	2.38e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—STAT3—Crohn's disease	3.61e-06	2.38e-05	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—IL6—Crohn's disease	3.6e-06	2.37e-05	CbGpPWpGaD
Vandetanib—ERBB3—Disease—IL6—Crohn's disease	3.6e-06	2.37e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—STAT3—Crohn's disease	3.6e-06	2.37e-05	CbGpPWpGaD
Vandetanib—LCK—Innate Immune System—IL6—Crohn's disease	3.59e-06	2.37e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—IL1B—Crohn's disease	3.57e-06	2.35e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—CD4—Crohn's disease	3.57e-06	2.35e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GPX4—Crohn's disease	3.57e-06	2.35e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—IFNG—Crohn's disease	3.55e-06	2.34e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—PTGS2—Crohn's disease	3.55e-06	2.34e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—TYK2—Crohn's disease	3.5e-06	2.3e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IL2RA—Crohn's disease	3.48e-06	2.29e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—TYK2—Crohn's disease	3.45e-06	2.27e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—STAT3—Crohn's disease	3.45e-06	2.27e-05	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—GCKR—Crohn's disease	3.44e-06	2.27e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—CD4—Crohn's disease	3.43e-06	2.26e-05	CbGpPWpGaD
Vandetanib—YES1—Immune System—IL6—Crohn's disease	3.42e-06	2.25e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—TYK2—Crohn's disease	3.38e-06	2.22e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—JAK2—Crohn's disease	3.34e-06	2.2e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—TYK2—Crohn's disease	3.32e-06	2.19e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—STAT3—Crohn's disease	3.32e-06	2.19e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—ALB—Crohn's disease	3.29e-06	2.17e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—JAK2—Crohn's disease	3.29e-06	2.17e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—STAT3—Crohn's disease	3.28e-06	2.16e-05	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—PTGS2—Crohn's disease	3.27e-06	2.15e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—JAK2—Crohn's disease	3.22e-06	2.12e-05	CbGpPWpGaD
Vandetanib—SRC—Innate Immune System—IL6—Crohn's disease	3.18e-06	2.09e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—JAK2—Crohn's disease	3.17e-06	2.09e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—STAT3—Crohn's disease	3.17e-06	2.09e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—IL1B—Crohn's disease	3.16e-06	2.08e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—CD4—Crohn's disease	3.16e-06	2.08e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—PTGS2—Crohn's disease	3.14e-06	2.07e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—STAT3—Crohn's disease	3.11e-06	2.05e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—STAT3—Crohn's disease	3.05e-06	2.01e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—CXCL8—Crohn's disease	3e-06	1.98e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—STAT3—Crohn's disease	3e-06	1.97e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—CXCL8—Crohn's disease	2.94e-06	1.93e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—CXCL8—Crohn's disease	2.89e-06	1.9e-05	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—PTGS2—Crohn's disease	2.88e-06	1.89e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—TYK2—Crohn's disease	2.87e-06	1.89e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—STAT3—Crohn's disease	2.87e-06	1.89e-05	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—IL6—Crohn's disease	2.86e-06	1.88e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—TYK2—Crohn's disease	2.77e-06	1.82e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—STAT3—Crohn's disease	2.77e-06	1.82e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—JAK2—Crohn's disease	2.74e-06	1.8e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—STAT3—Crohn's disease	2.65e-06	1.75e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—JAK2—Crohn's disease	2.64e-06	1.74e-05	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—IL6—Crohn's disease	2.62e-06	1.72e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Immune System—IL6—Crohn's disease	2.61e-06	1.72e-05	CbGpPWpGaD
Vandetanib—LYN—Immune System—IL6—Crohn's disease	2.55e-06	1.68e-05	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—IL6—Crohn's disease	2.55e-06	1.68e-05	CbGpPWpGaD
Vandetanib—ABL1—Immune System—IL6—Crohn's disease	2.54e-06	1.67e-05	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—IL6—Crohn's disease	2.52e-06	1.66e-05	CbGpPWpGaD
Vandetanib—FYN—Immune System—IL6—Crohn's disease	2.51e-06	1.66e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—CXCL8—Crohn's disease	2.5e-06	1.65e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—TYK2—Crohn's disease	2.45e-06	1.61e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—STAT3—Crohn's disease	2.45e-06	1.61e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—STAT3—Crohn's disease	2.41e-06	1.59e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—CXCL8—Crohn's disease	2.41e-06	1.59e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Disease—IL6—Crohn's disease	2.41e-06	1.59e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—IL6—Crohn's disease	2.38e-06	1.56e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—STAT3—Crohn's disease	2.36e-06	1.56e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—JAK2—Crohn's disease	2.34e-06	1.54e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—STAT3—Crohn's disease	2.33e-06	1.53e-05	CbGpPWpGaD
Vandetanib—FYN—Disease—IL6—Crohn's disease	2.32e-06	1.53e-05	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—IL6—Crohn's disease	2.29e-06	1.51e-05	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—IL6—Crohn's disease	2.21e-06	1.46e-05	CbGpPWpGaD
Vandetanib—EGFR—Immune System—IL6—Crohn's disease	2.17e-06	1.43e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—CXCL8—Crohn's disease	2.13e-06	1.4e-05	CbGpPWpGaD
Vandetanib—ABCC1—Disease—IL6—Crohn's disease	2.13e-06	1.4e-05	CbGpPWpGaD
Vandetanib—LCK—Immune System—IL6—Crohn's disease	2.09e-06	1.38e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—STAT3—Crohn's disease	2.01e-06	1.32e-05	CbGpPWpGaD
Vandetanib—EGFR—Disease—IL6—Crohn's disease	2.01e-06	1.32e-05	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—STAT3—Crohn's disease	1.94e-06	1.28e-05	CbGpPWpGaD
Vandetanib—LCK—Disease—IL6—Crohn's disease	1.93e-06	1.27e-05	CbGpPWpGaD
Vandetanib—SRC—Immune System—IL6—Crohn's disease	1.85e-06	1.22e-05	CbGpPWpGaD
Vandetanib—ALB—Metabolism—PTGS2—Crohn's disease	1.78e-06	1.17e-05	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—STAT3—Crohn's disease	1.72e-06	1.13e-05	CbGpPWpGaD
Vandetanib—SRC—Disease—IL6—Crohn's disease	1.71e-06	1.13e-05	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—IL6—Crohn's disease	1.69e-06	1.11e-05	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—IL6—Crohn's disease	1.65e-06	1.09e-05	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—IL6—Crohn's disease	1.63e-06	1.07e-05	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—IL6—Crohn's disease	1.4e-06	9.24e-06	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—IL6—Crohn's disease	1.35e-06	8.91e-06	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—IL6—Crohn's disease	1.2e-06	7.89e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—ALB—Crohn's disease	1.1e-06	7.21e-06	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—PTGS2—Crohn's disease	9.59e-07	6.31e-06	CbGpPWpGaD
